SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
Sandoz Group AG (SDZNY) Q2 2025 Earnings Call Transcript
Sandoz Group AG (OTCQX:SDZNY) Q2 2025 Earnings Conference Call August 7, 2025 3:00 AM ET Company Participants Craig Marks - Corporate Participant Head, IR - Corporate Participant Remco J. Steenbergen - Chief Financial Officer Richard Saynor - Chief Executive Officer Conference Call Participants Charlie Haywood - BofA Securities, Research Division Florent Cespedes - Sanford C.
Sandoz targets 70% price cut for weight-loss drugs in Canada, FT reports
Swiss generic drug manufacturer Sandoz plans to introduce unbranded weight-loss drugs in Canada at up to a 70% discount compared to branded versions when patents begin expiring next year, CEO Richard Saynor told the Financial Times.
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript
Sandoz Group AG (OTCQX:SDZNY) Q1 2025 Results Conference Call April 30, 2025 3:00 AM ET Company Participants Craig Marks - Head of Investor Relations Richard Saynor - Chief Executive Officer Remco Steenbergen - Chief Financial Officer Conference Call Participants Victor Floch - BNP Paribas Exane Harry Sephton - UBS Thibault Boutherin - Morgan Stanley Florent Cespedes - Bernstein Simon Baker - Redburn Atlantic James Gordon - JPMorgan Sidhartha Modi - Barclays Joris Zimmermann - Octavian Alistair Campbell - RBC Graham Parry - Bank of America Victoria Lambert - Berenberg Operator Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations, for his opening remarks.
Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access
The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global pricing inequities.
Sandoz: Upgrading To A Buy On 2028 Expectations
Upgraded Sandoz from "hold" to "buy on dips" due to strong cash flow, promising growth in generics, and mid-term EBITDA margin guidance of 24-26% by 2028. Sandoz's 2024 revenue grew 4%, with a core EBITDA margin of 20.1%, generating $622M in free cash flow, or $1.45/share. Anticipated 2025 core EBITDA margin of 21% and projected 2028 EPS of $3.37, with a potential current value of 41 CHF/share.
Sandoz family foundation offers $3 billion worth of Novartis shares
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuilt offering, according to the bookrunner.
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
